University of Michigan

University System of Maryland

Ludwig Institute for Cancer Research Limited

Eastern Michigan University

Dudley Strickland

Daniel Lawrence

Enming Joe Su

Manuel S Yepes

Ulf Eriksson

Linda Fredriksson

Cory Emal

Mark Warnock

Jacqueline Cale

Leonid Medved

Sergiy Yakovlev

The invention provides a method of treating inflammation, comprising administering to a subject in need thereof a therapeutically effective amount of an agent that inhibits binding of fibrin to Very Low Density Lipoprotein Receptor (VLDLR) or combination of this agent with agents inhibiting binding of fibrin to VE-cahherin (vascular endothelial cadherin).

Compositions for inhibiting fibrin-VLDL receptor-dependent inflammation and methods of treatment

Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-&#x3b1; antagonist.

Methods and compositions for modulation of blood-neural barrier

The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or condition associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to modulate lipid metabolism and treat conditions associated with elevated PAI-1, cholesterol, or lipid levels.

Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism

The present invention is a method of reducing vascular permeability in tissue of a subject comprising inhibiting the activity of serine proteinase tissue-type plasminogen activator (tPA). This tPA activity which increases permeability of the tissue in a subject results in edema in the tissue is separate from tPA's thrombolytic activity. The present invention more specifically relates to administering an amount of a tPA inhibitor sufficient to reduce the vascular permeability increasing activity of tPA in a subject. Useful tPA inhibitors for the present method are neuroserpin, mutant neuroserpin, wild-type PAI-1, mutant PAI-1, an antibody that binds to tPA, an antibody that binds to the low-density lipoprotein (LDL) receptor or a low-density lipoprotein (LDL) receptor family antagonist.

Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein

Growing community of inventors

Brookville, MD, United States of America

Dudley Strickland